Home / Current Issue / Paper 1713113
Evaluation of Lipid Profile Alterations and Their Clinical Significance Among Women with Polycystic Ovarian Syndrome in Kogi State, Nigeria.
Subject area: Biological & Medical Sciences · Area of research: Medical Sciences
Abstract
Polycystic Ovarian Syndrome (PCOS), a prevalent endocrine disorder among women of reproductive age and is frequently accompanied by metabolic disturbances that considerably elevate long-term cardiovascular risk. Among these abnormalities, dyslipidemia is one of the most common and clinically significant; however, evidence from sub-Saharan Africa, particularly Nigeria, remains limited. This study therefore evaluated lipid profile alterations and their clinical significance, with a focus on their contribution to metabolic and cardiovascular disease risk among women with PCOS in Kogi State, Nigeria. A cross-sectional analytical design was employed, involving 110 women diagnosed with PCOS and 40 age-matched controls without PCOS to make a total of 150 samples. Fasting blood samples were obtained for the assessment of lipid parameters, while anthropometric measurements were recorded to calculate cardiometabolic indices, including the Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP). Statistical analyses comprised group comparisons and correlation analyses to explore associations between lipid parameters and adiposity-related indices was employed. Women with PCOS exhibited a significantly more atherogenic lipid profile than controls, characterized by elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), alongside significantly reduced high-density lipoprotein cholesterol (HDL-C). Notably, the mean HDL-C level was markedly lower in the PCOS group (1.14 ? 0.39 mmol/L) compared with controls (1.47 ? 0.21 mmol/L; p < 0.001), consistent with the characteristic dyslipidemia which is associated with insulin resistance and hyperandrogenism in PCOS. Correlation analyses revealed that TG levels were moderately and positively associated with both body mass index (BMI) (r = 0.420, p < 0.001) and waist circumference (WC) (r = 0.455, p < 0.001), whereas HDL-C display significant inverse correlations with BMI (r = ?0.315, p = 0.001) and WC (r = ?0.340, p < 0.001). In contrast, LDL-C demonstrated no statistically significant association with BMI or WC. As expected from lipid physiology, total cholesterol showed a strong positive correlation with LDL-C (r = 0.835, p < 0.01), while LDL-C was moderately inversely correlated with HDL-C (r = ?0.548, p < 0.01). BMI also correlated positively with TC (r = 0.413, p < 0.01) and LDL-C (r = 0.546, p < 0.01), and negatively with HDL-C (r = ?0.402, p < 0.01), strengthening the role of adiposity in lipid dysregulation. LAP, an index derived from waist circumference and triglycerides, demonstrated a very strong positive correlation with TG (r = 0.720, p < 0.01), underscoring its sensitivity as a marker of visceral fat?related dyslipidemia. Generally, dyslipidemia particularly elevated TC, LDL-C, and TG was highly prevalent among women with PCOS in Kogi State, Nigeria and was closely associated with indices of visceral adiposity and elevated markers of myocardial injury or stress (cTnI, CK-MB, and myoglobin). These findings indicate a substantial burden of subclinical cardiometabolic risk among women with PCOS in this population. Incorporating simple, non-invasive adiposity indices such as VAI and LAP alongside with conventional lipid profiling may improve early risk categorization. Routine cardiometabolic screening and targeted preventive interventions are therefore recommended to extenuate the progression to expressed cardiovascular disease in women with PCOS.
Keywords
Polycystic Ovarian Syndrome, Dyslipidemia, Lipid Profile, Visceral Adiposity Index, Cardiometabolic Risk.
References
[1] Adewuni, D., Samuel, T. A., & Agbede, C. (2022). Metabolic syndrome associated with polycystic ovary syndrome in some Nigerian women. Pan African Journal of Life Sciences, 5(3), 1–11.
[2] Aggarwal, K., Agrawal, H., & Jain, A. (2019). Visceral adiposity index: Simple Tool for assessing cardiometabolic risk in women with polycystic ovary syndrome. Indian Journal of Endocrinology and Metabolism, 23(2), 232. https://doi.org/10.4103/ijem.ijem_559_18.
[3] Amato, M. C., Guarnotta, V., & Giordano, C. (2015). Visceral adiposity index: A reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care, 38(6), e92–e93. https://doi.org/10.2337/dc15-0280
[4] Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2(1). https://doi.org/10.1038/nrdp.2016.57.
[5] Bahmanpoori Ghalehzan, M., Afrasiabi, A., & Daneshmand, F. (2025). Polymorphism of the Insulin Resistin (RETN) gene in susceptibility to Polycystic Ovary Syndrome (PCOS) in an Iranian population.18 Journal of Functional Biomaterials, 16(1), 1–13.
[6] Barber, T. M., Hanson, P., Weickert, M. O., & Franks, S. (2019). Obesity and polycystic ovary syndrome: Implications for pathogenesis and novel management strategies. Clinical Medicine Insights: Reproductive Health, 13, 1–13. https://doi.org/10.1177/1179558119874042
[7] Berberich AJ, Hegele RA. (2022). A Modern Approach to Dyslipidemia. Endocr Rev. 43(4):611-653.
[8] Blasco M, Ascaso JF., (2019). en representación del grupo de Dislipidemia Aterogénica de la SEA. Control of the overall lipid profile. Clin Investig Arterioscler. Suppl 2:34-41.
[9] Dapas, M., & Dunaif, A. (2020). The contribution of excess adiposity to PCOS pathogenesis and cardiometabolic risk. Trends in Endocrinology & Metabolism, 31(10), 753–765. https://doi.org/10.1016/j.tem.2020.06.003
[10] Djuro Macut, Bačević, M., Božić-Antić, I., Jelica Bjekić-Macut, Milorad Čivčić, Erceg, S., Danijela Vojnović Milutinović, Olivera Stanojlović, Zoran Andrić, Biljana Kastratović-Kotlica, & Tijana Šukilović. (2015). Predictors of Subclinical Cardiovascular Disease in Women with Polycystic Ovary Syndrome: Interrelationship of Dyslipidemia and Arterial Blood Pressure. International Journal of Endocrinology, 2015, 1–9. https://doi.org/10.1155/2015/812610.
[11] Dumesic, D. A., Phan, J. D., Leung, K. L., Grogan, T. R., & Ding, X. (2016). Adipose insulin resistance in normal-weight women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism, 101(11), 4178–4186. https://doi.org/10.1210/jc.2016-2388
[12] Emokpae, M. A., Van-Lare, T. O., & Babatunde, E. M. (2024). Cardiovascular Risk is Independently Associated with Body Mass Index in Women with Polycystic Ovarian Syndrome in Lagos, Nigeria. Fertility & Reproduction, 06(03), 143–149. https://doi.org/10.1142/s2661318224500208.
[13] Emokpae, M., & Nwagbara, G. (2017). Serum Creatine Kinase-MB Isoenzyme Activity among Subjects with Uncomplicated Essential Hypertension: Any Sex Differences. Medical Sciences, 5(2), 8. https://doi.org/10.3390/medsci5020008.
[14] Escobar-Morreale, H. F. (2018). Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology, 14(5), 270–284. https://doi.org/10.1038/nrendo.2018.24
[15] Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2017). Evolving concepts concerning the management of elevated LDL-cholesterol: From observational epidemiology to randomized trials. The Lancet, 390(10114), 2718–2729. https://doi.org/10.1016/S0140-6736(17)31961-3
[16] Ghosh, A., Bir, A., & Chowdhury, S. (2023). Visceral adiposity index and lipid accumulation product index: The promising role in assessing cardiometabolic risk in non-obese patients of PCOS. Journal of Education and Health Promotion, 12(1), 148–148. https://doi.org/10.4103/jehp.jehp_1605_22.
[17] Glintborg, D., Rubin, K. H., Nybo, M., Abrahamsen, B., & Andersen, M. (2018). Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovascular Diabetology, 17(1). https://doi.org/10.1186/s12933-018-0680-5.
[18] Guan, C., Zahid, S., Minhas, A. S., Ouyang, P., Vaught, A., Baker, V. L., & Michos, E. D. (2022). Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertility and Sterility, 117(5), 924–935. https://doi.org/10.1016/j.fertnstert.2022.03.009.
[19] Ige, I. P., Mokwenye, N. V., Emokpae A. M., Ilesanmi-Ige, I. T. Ugbomoiko, O. D., Obadire, S. O., Obadire, F. O., Theophilus, E. O., Aghatise, K. (2024). “Evaluation of Glycated Hemoglobin and Fasting Lipid Panels as Glucose Monitoring Markers among Nigerian Populace with Type 2 Diabetes and Cardiovascular Disease”. Clinical Trials and Clinical Research, 3(5):
[20] Karantas ID, Okur ME, Okur NÜ, Siafaka PI. (2021). Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives. Endocr Metab Immune Disord Drug Targets. 21(5):815-834.
[21] Khan, M. J., Ullah, A., Basit, S., & Shafi, S. (2025). The molecular basis of polycystic ovary syndrome and its cardiometabolic correlates: Exploring the intersection and its clinical implications—A narrative review. Biology, 13(3), 709.
[22] Khan, S. U., Lone, A. N., Khan, M. S., & Kaluski, E. (2025). Atherogenic dyslipidemia and cardiovascular risk in polycystic ovary syndrome. Trends in Cardiovascular Medicine, 35(1), 12–21.
[23] Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2017). Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 102(2), 456–473. https://doi.org/10.1210/jc.2016-000
[24] Levine, H., Jørgensen, N., Martino-Andrade, A., Mendiola, J., Weksler-Derri, D., Mindlis, I., Pinotti, R., & Swan, S. H. (2017). Temporal trends in sperm count: a systematic review and meta-regression analysis. Human Reproduction Update, 23(6), 646–659. https://doi.org/10.1093/humupd/dmx022.
[25] Lim, S. S., Kakoly, N. S., Tan, J. W. J., Fitzgerald, G., Bahri Khomami, M., Joham, A. E., … Teede, H. J. (2019). Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Obesity Reviews, 20(2), 339–352. https://doi.org/10.1111/obr.12762
[26] Lippi, G., Cervellin, G., & Mattiuzzi, C. (2016). Relationship of circulating troponins with lipid profiles. Clinical Biochemistry, 49(15), 1196–1200. (Discusses troponin and lipids association).
[27] Lugo-Somolinos A, Sánchez JE. (2003). Xanthomas: a marker for hyperlipidemias. Bol Asoc Med P R. 95(4):12-6.
[28] Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Panagiotakos, B. P., Petukhova, S., Tokgozoglu, L., Zamorano, J. L., & 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2018). European Heart Journal, 40(39), 3433–3454. https://doi.org/10.1093/eurheartj/ehz455
[29] Mahmoud, F. A., & El-Ghitany, E. M. (2022). Dyslipidemia and cardiovascular risk in women with polycystic ovary syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 16(4), 102476. https://doi.org/10.1016/j.dsx.2022.102476
[30] Mahmoud, S., & El-Ghitany, E. M. (2022). Dyslipidaemia in polycystic ovary syndrome: Patterns and cardiovascular implications. Endocrine Connections, 11(5), e210558.
[31] Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2015). Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction Update, 21(5), 656–670. https://doi.org/10.1093/humupd/dmv025
[32] Nandakumar Manjula, Das, P., Thozhukat Sathyapalan, Butler, A. E., & Atkin, S. L. (2024). Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome. Biomolecules, 15(1), 4–4. https://doi.org/10.3390/biom15010004.
[33] Odigie, F., Enyinna, C. O., Agbor, R. N., & Okereke, C. (2022). Insulin resistance and its associated risk factors in Nigerian women with polycystic ovary syndrome. Open Journal of Endocrine and Metabolic Diseases, 12(4), 163–175.
[34] Odigie, F., Enyinna, C. O., Agbor, R. N., & Okereke, C. (2022). Insulin resistance and its associated risk factors in Nigerian women with polycystic ovary syndrome. Open Journal of Endocrine and Metabolic Diseases, 12(4), 163–175.
[35] Omokanye, L. O., Adewuyi, A. S., Bako, L. A., Ahmed, F. A., & Ajiboye, A. B. (2015). Polycystic Ovarian Syndrome: Analysis of management outcomes among infertile women at a public health institution in Nigeria. Nigerian Journal of General Practice, 16(2), 65–70.
[36] Omran, F., Kyrou, I., Osman, F., Lim, V. G., Randeva, H. S., & Chatha, K. (2022). Cardiovascular Biomarkers: Lessons of the Past and Prospects for the Future. International Journal of Molecular Sciences, 23(10), 5680. https://doi.org/10.3390/ijms23105680.
[37] Papathanasiou, K. A. (2024). Lipid accumulation product and cardiovascular risk: Implications for women with PCOS. Cardiovascular Research Communications, 11(10), 316.
[38] Pappan, N., Rehman, A., & Awosika, A. O. (2024). Dyslipidemia. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK560891/.
[39] Patel, P., & Mishra, M. (2023). Visceral adiposity index and lipid accumulation product index: Cardiometabolic risk in PCOS. Journal of Education and Health Promotion. (Shows VAI/LAP associations).
[40] Ranasinha, S., Joham, A. E., Norman, R. J., & Teede, H. J. (2015). The association between polycystic ovary syndrome and metabolic syndrome: A statistical modelling approach. Clinical Endocrinology, 83(6), 879–887. https://doi.org/10.1111/cen.12842
[41] Ranasinha, S., Joham, A. E., Norman, R. J., & Teede, H. J. (2015). The association between polycystic ovary syndrome and metabolic syndrome: A statistical modelling approach. Clinical Endocrinology, 83(6), 879–887. https://doi.org/10.1111/cen.12842
[42] Rizzo, M., Berneis, K., Carmina, E., & Caruso, C. (2016). How should we manage atherogenic dyslipidemia in polycystic ovary syndrome? American Journal of Obstetrics and Gynecology, 215(6), 725–735. https://doi.org/10.1016/j.ajog.2016.07.042
[43] Rizzo, M., Berneis, K., Spinas, G., & Rini, G. B. (2021). Lipid abnormalities in polycystic ovary syndrome: Role of insulin resistance and androgen excess. Journal of Endocrinological Investigation, 44(2), 229–237. https://doi.org/10.1007/s40618-020-01342-6
[44] Sur, D., & Chakravorty, R. (2023). Association of Coronary Heart Disease Risk and Lipid Profile in Indian Women With Polycystic Ovarian Syndrome. Journal of Clinical Gynecology and Obstetrics, 5(1), 23–26. https://doi.org/10.14740/jcgo375w.
[45] Teede, H. J., Joham, A. E., Paul, E., Moran, L. J., Loxton, D., Jolley, D., & Lombard, C. (2023). Longitudinal weight gain in women identified with polycystic ovary syndrome: Results of an observational study. The Journal of Clinical Endocrinology & Metabolism, 108(4), 911–920. https://doi.org/10.1210/clinem/dgac658
[46] Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., & Norman, R. J. (2018). Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction, 33(9), 1602–1618. https://doi.org/10.1093/humrep/dey256
[47] Visceral Adiposity Index (2019): Simple Tool for Assessing Cardiometabolic Risk in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism. (PCOS and VAI).
[48] Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., … Yildiz, B. O. (2020). Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement. The Journal of Clinical Endocrinology & Metabolism, 105(9), 1–25. https://doi.org/10.1210/clinem/dgaa226
[49] Wild, R. A., Rizzo, M., Clifton, S., & Carmina, E. (2018). Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertility and Sterility, 110(4), 698–710. https://doi.org/10.1016/j.fertnstert.2018.05.022
[50] Yang, T., Cao, H., & Yuan, X. (2025). Predictive value of cardiac markers, atherogenic index of plasma and cardiometabolic index for coronary heart disease in type 2 diabetes mellitus patients with normal body mass index. The American Journal of the Medical Sciences, 370(5), 428–435. https://doi.org/10.1016/j.amjms.2025.07.017.
[51] Zhao, H., Li, S.-P., Shi, Y., Liu, Y., Wang, P.-H., & Chang, X. (2020). Insulin resistance in polycystic ovary syndrome across tissues: mechanisms and therapeutic strategies. Ovarian Research, 16(1), 91. https://doi.org/10.1186/s13048-022-01091-0
[52] Zhao, H., Zhang, J., Cheng, X., Nie, X., & He, B. (2023). Insulin resistance in polycystic ovary syndrome across various tissues: An updated review of pathogenesis, evaluation, and treatment. Journal of Ovarian Research, 16, Article 9. https://doi.org/10.1186/s13048-022-01091-0
How to cite this paper
@article{1713113,
author = {Ohikere, O. P., Mokwenye, N. V., Emokpae A. M., Ige, I. P., Ugbomoiko, O. D.; Folagbade, O. B.},
title = {Evaluation of Lipid Profile Alterations and Their Clinical Significance Among Women with Polycystic Ovarian Syndrome in Kogi State, Nigeria.},
journal = {Iconic Research And Engineering Journals},
year = {2025},
volume = {9},
number = {6},
pages = {2374-2393},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1713113.pdf},
abstract = {Polycystic Ovarian Syndrome (PCOS), a prevalent endocrine disorder among women of reproductive age and is frequently accompanied by metabolic disturbances that considerably elevate long-term cardiovascular risk. Among these abnormalities, dyslipidemia is one of the most common and clinically significant; however, evidence from sub-Saharan Africa, particularly Nigeria, remains limited. This study therefore evaluated lipid profile alterations and their clinical significance, with a focus on their contribution to metabolic and cardiovascular disease risk among women with PCOS in Kogi State, Nigeria. A cross-sectional analytical design was employed, involving 110 women diagnosed with PCOS and 40 age-matched controls without PCOS to make a total of 150 samples. Fasting blood samples were obtained for the assessment of lipid parameters, while anthropometric measurements were recorded to calculate cardiometabolic indices, including the Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP). Statistical analyses comprised group comparisons and correlation analyses to explore associations between lipid parameters and adiposity-related indices was employed. Women with PCOS exhibited a significantly more atherogenic lipid profile than controls, characterized by elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG), alongside significantly reduced high-density lipoprotein cholesterol (HDL-C). Notably, the mean HDL-C level was markedly lower in the PCOS group (1.14 ? 0.39 mmol/L) compared with controls (1.47 ? 0.21 mmol/L; p < 0.001), consistent with the characteristic dyslipidemia which is associated with insulin resistance and hyperandrogenism in PCOS. Correlation analyses revealed that TG levels were moderately and positively associated with both body mass index (BMI) (r = 0.420, p < 0.001) and waist circumference (WC) (r = 0.455, p < 0.001), whereas HDL-C display significant inverse correlations with BMI (r = ?0.315, p = 0.001) and WC (r = ?0.340, p < 0.001). In contrast, LDL-C demonstrated no statistically significant association with BMI or WC. As expected from lipid physiology, total cholesterol showed a strong positive correlation with LDL-C (r = 0.835, p < 0.01), while LDL-C was moderately inversely correlated with HDL-C (r = ?0.548, p < 0.01). BMI also correlated positively with TC (r = 0.413, p < 0.01) and LDL-C (r = 0.546, p < 0.01), and negatively with HDL-C (r = ?0.402, p < 0.01), strengthening the role of adiposity in lipid dysregulation. LAP, an index derived from waist circumference and triglycerides, demonstrated a very strong positive correlation with TG (r = 0.720, p < 0.01), underscoring its sensitivity as a marker of visceral fat?related dyslipidemia. Generally, dyslipidemia particularly elevated TC, LDL-C, and TG was highly prevalent among women with PCOS in Kogi State, Nigeria and was closely associated with indices of visceral adiposity and elevated markers of myocardial injury or stress (cTnI, CK-MB, and myoglobin). These findings indicate a substantial burden of subclinical cardiometabolic risk among women with PCOS in this population. Incorporating simple, non-invasive adiposity indices such as VAI and LAP alongside with conventional lipid profiling may improve early risk categorization. Routine cardiometabolic screening and targeted preventive interventions are therefore recommended to extenuate the progression to expressed cardiovascular disease in women with PCOS.},
keywords = {Polycystic Ovarian Syndrome, Dyslipidemia, Lipid Profile, Visceral Adiposity Index, Cardiometabolic Risk.},
month = {December},
doi = {https://doi.org/10.64388/IREV9I6-1713113}
}